Markets:

Overview

News

Currencies

International

Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

233.34 -2.46 (-1.04%)

Streaming Delayed Price Updated: 2:50 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗

January 29, 2024

The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.

Via Benzinga

Topics Artificial Intelligence

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 16, 2024

Via Benzinga

Expert Ratings for Krystal Biotech ↗

December 13, 2023

Via Benzinga

This Stock Has Quadrupled in 5 Years. Can It Do It Again? ↗

November 10, 2023

Have investors already missed the boat with this stock?

Via The Motley Fool

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

A Preview Of Krystal Biotech's Earnings ↗

November 03, 2023

Via Benzinga

5 Analysts Have This to Say About Krystal Biotech ↗

October 12, 2023

Via Benzinga

5 Analysts Have This to Say About Krystal Biotech ↗

September 07, 2023

Via Benzinga

Analyst Ratings for Krystal Biotech ↗

August 08, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

Expert Ratings for Krystal Biotech ↗

July 03, 2023

Via Benzinga

What Will AbbVie Buy Next? ↗

June 28, 2023

Two mid-cap drugmakers stand out as logical targets for AbbVie.

Via The Motley Fool

Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8

June 08, 2023

Via Investor Brand Network

Up 48% in 2023, Is This Biotech Stock a Buy? ↗

June 03, 2023

How much longer can this biotech's run last?

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023 ↗

October 12, 2023

Via Benzinga

Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M ↗

August 21, 2023

Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)

Via Benzinga

3 Biotech Stocks to Buy Before the Breakout ↗

July 28, 2023

Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch.

Via InvestorPlace

Why Shares of Krystal Biotech Are Rising Monday ↗

May 22, 2023

The company is moving quickly to market its newly approved therapy.

Via The Motley Fool

Analyst Expectations for Krystal Biotech's Future ↗

May 22, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023 ↗

September 07, 2023

Via Benzinga

2 Soaring Stocks With More Upside Potential ↗

July 21, 2023

Are these mid-cap stocks giants in the making?

Via The Motley Fool

Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 07, 2023

Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...

Via Benzinga

Arbutus Appoints Two New Executives

July 10, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter ↗

June 06, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Krystal Clear: Krystal Biotech Clears Resistance in Good Volume

May 30, 2023

Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.

Via MarketBeat

Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™

May 23, 2023

From Option Care Health, Inc.

Via GlobeNewswire

Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment ↗

May 22, 2023

The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with

Via Benzinga

Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action

May 22, 2023

Via Investor Brand Network

FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder ↗

May 22, 2023

The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

All News about Krystal Biotech, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today